Check out this week's QuadCast as we discuss if PCV is better than TMZ for oligodendroglioma, discuss results of the hypo-FLAME trial for prostate cancer, highlight adjuvant RT for high risk bladder cancer in the BART trial, and more.
Check out this week's QuadCast as we discuss if PCV is better than TMZ for oligodendroglioma, discuss results of the hypo-FLAME trial for prostate cancer, highlight adjuvant RT for high risk bladder cancer in the BART trial, and more.